Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs BMS-986263 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Acronyms JUNIPER
- Sponsors Nitto Denko
- 21 Nov 2022 This trial has been completed in United States according to European Clinical Trials Database record.
- 20 Nov 2022 This trial has been completed in Germany (End Date: 24 Aug 2022) according to European Clinical Trials Database record.
- 02 Dec 2021 Status changed from recruiting to active, no longer recruiting.